• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Effector Therapeutics Inc (NQ: EFTR )

    0.1800 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.1800
    Bid (Size) 0.1400 (3)
    Ask (Size) 0.1550 (11)
    Prev. Close 0.1800
    Today's Range 0.1800 - 0.1800
    52wk Range 0.1800 - 17.90
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
    Explore bankruptcy risk stocks with insights on Chicken Soup for the Soul Entertainment, eFFECTOR Therapeutics, and Delta Apparel. 
    Via InvestorPlace
    Topics Bankruptcy
    Exposures Financial Legal
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
    Via InvestorPlace

    Performance

    YTD
    -98.53%
    -98.53%
    1 Month
    N/A
    N/A
    3 Month
    N/A
    N/A
    6 Month
    -91.55%
    -91.55%
    1 Year
    -98.64%
    -98.64%

    More News

    Read More
    Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
    Via Benzinga
    eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
    Via Benzinga
    Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From eFFECTOR Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.